DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Sarrazin C, Cooper CL, Manns MP. , et al.
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
J Hepatol 2018;
69 (06) 1221-1230
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.